Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx (NYSE AMERICAN: VNRX) has announced its first commercial sale of their High Throughput Synthetic Sepsis method, a breakthrough technology that measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood in real time. This innovative approach helps companies develop new therapeutics for sepsis and NETs-related diseases.
The technology addresses significant limitations in previous research by measuring NETs directly in whole blood, avoiding potential alterations in neutrophil responses caused by isolation procedures. The method provides a more physiologically relevant environment for studying neutrophil responses and enables precise measurement of NETs formation.
Sepsis, responsible for approximately 370,000 US deaths annually, involves NETs which are essential for trapping and neutralizing pathogens. However, their overproduction can lead to tissue damage and disease progression. This new technology aims to enhance understanding of conditions characterized by uncontrolled NETs formation and serve as a key tool in translational research.
VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for February 14, 2025, at 8:00 AM ET. The event, titled 'Casting a New Light on Sepsis Management,' will feature presentations from Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre, Chief Commercial Officer.
Dr. Retter will discuss Nu.Q® NETs H3.1, a novel biomarker for early mortality and organ dysfunction in sepsis, which also serves as an independent predictor for renal replacement therapy needs. Recent large-scale study results suggest potential clinical applications in risk stratification and early intervention for critically ill sepsis patients.
Mr. Forterre will provide updates on Volition's commercialization strategies through licensing and sales channels. The event will conclude with a live Q&A session.
VolitionRx (NYSE AMERICAN: VNRX) has announced significant results from a large-scale study of its Nu.Q®NETs H3.1 biomarker in sepsis patients. The study, analyzing plasma samples from 971 patients with sepsis and septic shock, demonstrates that the biomarker can independently predict 28-day mortality and need for renal replacement therapy.
The research reveals higher biomarker levels in septic shock compared to sepsis patients, showing a dose-response relationship with acute kidney injury severity. The study suggests Nu.Q® NETs H3.1's potential for risk stratification and early intervention in critically ill sepsis patients.
The company is currently engaged in commercial discussions with major diagnostic industry players, particularly focusing on the sepsis market. The technology aims to provide simple, cost-effective blood tests for disease diagnosis and monitoring in both humans and animals.
VolitionRx (NYSE AMERICAN: VNRX) has released its 2024 Business Review, highlighting significant achievements in expanding its diagnostic technologies. The company's Nu.Q® Vet Cancer Test reached 20 countries worldwide, with over 110,000 tests sold in the first three quarters of 2024.
Key developments include hosting a Satellite Symposium showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients, strengthening their patent portfolio, and making progress in clinical and research programs within their cancer pillar. The company has initiated commercial discussions for out-licensing opportunities in sepsis and oncology liquid biopsy markets.
Volition also strengthened its Board of Directors with the appointment of Timothy Still as chair and Dr. Ethel Rubin as Independent Director, both bringing significant commercial and financing experience in diagnostics.
VolitionRx (NYSE AMERICAN: VNRX) has appointed LifeSci Advisors (LSA) as its investor relations consultants. The company, which specializes in epigenetics, made this announcement following significant progress in 2024, including the launch of Nu.Q® Vet Cancer Test in the U.S. and Europe through Antech.
The company plans to participate in the 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025, at the Beacon Grand Hotel in San Francisco, coinciding with the J.P. Morgan Health Care Conference. Volition anticipates multiple financial and value-creating operating milestones in human applications for both cancer and sepsis in 2025.
VolitionRx (NYSE AMERICAN: VNRX) announced results from an 800-patient study showing its Nu.Q® Cancer Test can differentiate between malignant and benign pulmonary nodules found by Low Dose CT (LDCT) scan in lung cancer screening. The study, led by Professor Jin-Shing Chen at National Taiwan University Hospital, revealed that a panel of two Nu.Q® nucleosome quantification assays achieved 92% diagnostic sensitivity and 89% Positive Predictive Value when combined with LDCT screening.
A 500-patient validation study in a real-world setting is planned to begin this year, with completion expected in 2025. If successful, the test could be included in Taiwan's National Lung Cancer Screening Program, potentially reducing unnecessary biopsies and surgeries for patients with benign nodules.
VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering expected to raise up to $1.9 million in gross proceeds. The offering includes the sale of 445,648 shares to company insiders at $0.5722 per share, and 2,857,389 shares with warrants to other investors at the same price.
The offering includes Form A warrants to purchase up to 2,857,389 shares at $0.5722 per share and Form B warrants for up to 1,428,693 shares at $0.71525 per share, both exercisable immediately with a 5-year expiration. If fully exercised, the warrants could generate additional gross proceeds of approximately $2.7 million.
The company plans to use the proceeds for research, product development, clinical studies, commercialization, and working capital.
VolitionRx (VNRX) reported strong Q3 2024 results, with revenue reaching $475,000, up 187% year-over-year. Year-to-date revenue hit $1 million, a 96% increase from the previous year. The company sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters of 2024, with the test now available in 17 countries. Cash position stood at $5.4 million as of September 30, with an additional $2.2 million in non-dilutive funding secured from the Walloon Region, Belgium. The company aims to achieve cash neutrality in 2025.
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time to discuss their third quarter 2024 financial and operating results, along with a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera, and Dr. Andrew Retter. A live audio webcast will be available, and a telephone replay will be accessible until November 29, 2024.
VolitionRx (NYSE AMERICAN: VNRX) has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Still brings over 35 years of experience in medical diagnostics, devices, and digital health. He previously served as President and CEO of Sense Biodetection and held leadership positions at various medical technology companies. His most recent role was at TSTILL Enterprises as Chairman and CEO, while also serving as an Operating Partner with REVIVAL Healthcare. Still holds an MBA from USC and a BS from UC Davis. The appointment comes at what the company describes as a pivotal time in its development of epigenetic technology for disease detection and monitoring.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
What does VolitionRx Limited do?
Where is VolitionRx Limited based?
What is the Nu.Q® Vet Cancer Test?
What are VolitionRx's recent achievements?
What is the Nucleosomics™ platform?
How is VolitionRx planning to achieve cash flow neutrality by 2025?
How can I get more information about VolitionRx?
What diseases does VolitionRx target with its tests?
What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?
What upcoming milestones does VolitionRx expect?
